Clinical Research Directory
Browse clinical research sites, groups, and studies.
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Sponsor: Klus Pharma Inc.
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Official title: A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2023-01-17
Completion Date
2027-12-31
Last Updated
2025-10-14
Healthy Volunteers
No
Conditions
Interventions
SKB264
be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
Pembrolizumab
be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
Locations (48)
Community Clinical Research Center
Anderson, Indiana, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Anne Arundel Medical Center (AAMC)
Annapolis, Maryland, United States
UT Health East Texas - Hope Cancer Center Tyler
Tyler, Minnesota, United States
Westchester Medical Center
Hawthorne, New York, United States
Texas Oncology, P.A. Amarillo, TX
Amarillo, Texas, United States
Texas Oncology, P.A. Austin, TX
Austin, Texas, United States
Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, VA
Roanoke, Virginia, United States
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Flinders Medical Centre
Bedford Park, Australia
Wollongong Hospital
Kogarah, Australia
Algemeen Ziekenhuis Klina
Brasschaat, Belgium
Grand Hôpital de Charleroi - Site Notre-Dame
Charleroi, Belgium
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
BC Cancer - Kelowna
Kelowna, British Columbia, Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Canada
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Jilin Cancer Hospital
Changchun, Jinlin, China
The Second Hospital of Dalian
Dalian, Liaoning, China
Weifang People's Hospital
Weifang, Shandong, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Jilin University
Changchun, China
Hunan Cancer Hospital
Changsha, China
Chongqing Cancer Hospital
Chongqing, China
Sun Yat-sen Memorial Hospital
Guangzhou, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Qilu Hosptial of Qlilu University
Jinan, China
Shandong Cancer Hospital
Jinan, China
Nanjing Drum Tower Hospital
Nanjing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Obstetrics and Gynecology Hospital Affiliated to Fudan University
Shanghai, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
Wuhan, China
Zhongnan Hospital of Wuhan University
Wuhan, China
Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou Universit
Zhengzhou, China
Henan Cancer Hospital
Zhengzhou, China
The first Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Szpitale Pomorskie Sp. z o.o.
Gdynia, Poland
Pratia MCM Krakow
Krakow, Poland
Biokinetica S.A., Przychodnia Jozefow
Warsaw, Poland